Skip to Main Content

Paper Details

Combination of Crizotinib and Osimertinib in T790M+ EGFR-Mutant Non-Small Cell Lung Cancer with Emerging MET Amplification Post-Osimertinib Progression in a 10-Year Survivor: A Case Report.
Case Rep Oncol
5
2021
Author NameAffiliation
Daniel KazdalInstitute of Pathology, University Hospital Heidelberg
Daniel KazdalTranslational Lung Research Center (TLRC) Heidelberg, German Center for Lung Research (DZL)
Anna-Lena VolckmarInstitute of Pathology, University Hospital Heidelberg
Martina KirchnerInstitute of Pathology, University Hospital Heidelberg
Albrecht StenzingerInstitute of Pathology, University Hospital Heidelberg
Albrecht StenzingerTranslational Lung Research Center (TLRC) Heidelberg, German Center for Lung Research (DZL)
  • 1 - 6

Datasets

Release 1.2